Will stem cells from fat and growth factors from blood bring new hope to female patients with reproductive disorders?
| Autor: | Raana Sarvari, Hamed Hamishehkar, Samira Asghari, Alireza Yousefzadeh Khiabani, Amir Valizadeh, Alexander M. Seifalian, Ata Mahmoodpoor, Sepideh Jalilzadeh Razin, Peyman Keyhanvar, Neda Keyhanvar, Mohammad Nouri, Shima Tavakol, Sepideh Bastani, Saeed Heidari Keshel, Bahman Yousefi, Alireza Shoae-Hassani, Mehdi Yousefi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Infertility medicine.medical_treatment Female reproductive system Bioinformatics Regenerative Medicine Regenerative medicine 03 medical and health sciences 0302 clinical medicine Endocrinology Medicine Humans Reproductive health 030219 obstetrics & reproductive medicine business.industry Growth factor Stem Cells Stromal vascular fraction medicine.disease 030104 developmental biology Animal Science and Zoology Female Hormone therapy Stem cell business Infertility Female Developmental Biology Stem Cell Transplantation |
| Zdroj: | Reproductive biology. 21(2) |
| ISSN: | 2300-732X |
| Popis: | Female reproductive system disorders (FRSD) with or without infertility are prevalent women's health problems with a variety of treatment approaches including surgery and hormone therapy. It currently considering to sub-branch of regenerative medicine including stem cells or growth factors injection-based delivery treatment might be improved female reproductive health life. The most common products used for these patients treatment are autologous cell or platelet-based products from patients, including platelet-rich plasma, plasma rich in growth factor, platelet-rich fibrin, and stromal vascular fraction. In this review, we discuss each of the above products used in treatment of FRSD and critically evaluate the clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect